Italy-based global pharmaceutical company Recordati will advance to the Korean rare disease treatment market.

Celebrating Rare Disease Day falling on Tuesday this week, Recordati Korea made the announcement last Friday that it would begin a business as the Italian pharma giant’s local offshoot and its Asia-Pacific headquarters.

Recordati has a history of more than 90 years. The company acquired EUSA Pharma, a U.K. company, to enhance its rare disease treatment portfolio. Accordingly, EUSA Pharma Korea also changed its name to Recordati Korea.

Recordati Korea plans to supply several rare disease treatments, including Sylvant (siltuximab), treatment for multicentric Castleman’s disease (MCD), Carbaglu (carglumic acid), treatment for hyperammonemia, and others that treat neuroblastoma and Cushing’s syndrome.

“By acquiring EUSA Pharma, Recordati has expanded its portfolio to rare children’s cancer and blood diseases in addition to the existing specialty of metabolic and endocrine rare disease treatments,” Recordati Korea CEO Lee Yeon-jae said. “Based on our expanded portfolio, we will strive to develop and supply rare disease treatments with high unmet needs but limited treatment options.”

Lee added that Recordati Korea would focus on creating an environment where the company can find out hidden MCD patients and treat them from the early stage using Sylvant.